Caverject

Impotence, Aquaporin 2, Raynaud Disease
Treatment
20 Active Studies for Caverject

What is Caverject

AlprostadilThe Generic name of this drug
Treatment SummaryAlprostadil is a medication used to relax blood vessels and increase blood flow. In infants with heart defects, it is used to keep the ductus arteriosus open until corrective surgery can be performed. In adults, it is used to treat erectile dysfunction due to a variety of causes.
Prostin Vr Pediatricis the brand name
image of different drug pills on a surface
Caverject Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prostin Vr Pediatric
Alprostadil
1981
28

Effectiveness

How Caverject Affects PatientsAlprostadil (a form of prostaglandin E1) is a natural substance that causes blood vessels to relax and expand, allowing better blood flow. In adults, this improved blood flow can help men achieve an erection. In infants, this drug can help increase the amount of blood flowing through the lungs and body.
How Caverject works in the bodyAlprostadil works by relaxing the muscles of the arteries and ductus arteriosus (DA). This increases blood flow in the lungs, effective aortic diameter, and systemic blood flow to the lower body. In adults, it increases blood flow to the penis, filling up the lacunar spaces and causing it to become rigid. This improved blood flow leads to better tissue oxygen supply and renal perfusion.

When to interrupt dosage

The proposed dose of Caverject is contingent upon the indicated condition, including Impotence, Raynaud's Phenomenon and Aquaporin 2. The amount of dosage varies depending on the method of delivery laid out in the table below.
Condition
Dosage
Administration
Impotence
, 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, 0.01 mg/mL, 0.02 mg/mL, 0.04 mg/mL, 0.0232 mg, 0.0119 mg, 0.0105 mg/mL, 0.0054 mg/mL, 0.5 mg/mL, 0.0205 mg/mL, 0.1 mg/mL, 0.0411 mg/mL, 0.2 mg/mL, 0.02 mg, 0.0033 mg/mg, 0.0022 mg/mg
, Urethral, Suppository, Suppository - Urethral, Intracavernous, Injection, powder, lyophilized, for solution - Intracavernous, Injection, powder, lyophilized, for solution, Kit; Liquid; Powder, for solution - Intracavernous, Kit; Liquid; Powder, for solution, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution, Liquid, Liquid - Intra-arterial; Intravenous, Powder, for solution - Intracavernous, Powder, for solution, Topical, Cream - Topical, Cream, Intravascular, Injection, solution, concentrate, Injection, solution, concentrate - Intravascular, Intravascular; Intravenous, Injection, solution, Injection, solution - Intravascular; Intravenous, Solution - Intravascular, Injection, Injection - Intravascular; Intravenous
Aquaporin 2
, 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, 0.01 mg/mL, 0.02 mg/mL, 0.04 mg/mL, 0.0232 mg, 0.0119 mg, 0.0105 mg/mL, 0.0054 mg/mL, 0.5 mg/mL, 0.0205 mg/mL, 0.1 mg/mL, 0.0411 mg/mL, 0.2 mg/mL, 0.02 mg, 0.0033 mg/mg, 0.0022 mg/mg
, Urethral, Suppository, Suppository - Urethral, Intracavernous, Injection, powder, lyophilized, for solution - Intracavernous, Injection, powder, lyophilized, for solution, Kit; Liquid; Powder, for solution - Intracavernous, Kit; Liquid; Powder, for solution, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution, Liquid, Liquid - Intra-arterial; Intravenous, Powder, for solution - Intracavernous, Powder, for solution, Topical, Cream - Topical, Cream, Intravascular, Injection, solution, concentrate, Injection, solution, concentrate - Intravascular, Intravascular; Intravenous, Injection, solution, Injection, solution - Intravascular; Intravenous, Solution - Intravascular, Injection, Injection - Intravascular; Intravenous
Raynaud Disease
, 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, 0.01 mg/mL, 0.02 mg/mL, 0.04 mg/mL, 0.0232 mg, 0.0119 mg, 0.0105 mg/mL, 0.0054 mg/mL, 0.5 mg/mL, 0.0205 mg/mL, 0.1 mg/mL, 0.0411 mg/mL, 0.2 mg/mL, 0.02 mg, 0.0033 mg/mg, 0.0022 mg/mg
, Urethral, Suppository, Suppository - Urethral, Intracavernous, Injection, powder, lyophilized, for solution - Intracavernous, Injection, powder, lyophilized, for solution, Kit; Liquid; Powder, for solution - Intracavernous, Kit; Liquid; Powder, for solution, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution, Liquid, Liquid - Intra-arterial; Intravenous, Powder, for solution - Intracavernous, Powder, for solution, Topical, Cream - Topical, Cream, Intravascular, Injection, solution, concentrate, Injection, solution, concentrate - Intravascular, Intravascular; Intravenous, Injection, solution, Injection, solution - Intravascular; Intravenous, Solution - Intravascular, Injection, Injection - Intravascular; Intravenous

Warnings

Caverject has fourteen contraindications. It should not be taken when someone is exhibiting any of the conditions outlined in the subsequent table.Caverject Contraindications
Condition
Risk Level
Notes
predisposition to multiple myeloma
Do Not Combine
penis
Do Not Combine
Polycythemia
Do Not Combine
Thrombocytosis
Do Not Combine
predisposition to priapism
Do Not Combine
Disease
Do Not Combine
Coitus
Do Not Combine
penile implants
Do Not Combine
leukemia
Do Not Combine
Anemia, Sickle Cell
Do Not Combine
Pulse Frequency
Do Not Combine
Erectile Dysfunction
Do Not Combine
Hyperviscosity syndrome
Do Not Combine
Pulse Frequency
Do Not Combine
There are 17 known major drug interactions with Caverject.
Common Caverject Drug Interactions
Drug Name
Risk Level
Description
Captopril
Minor
The excretion of Captopril can be decreased when combined with Alprostadil.
Cefdinir
Minor
The excretion of Cefdinir can be decreased when combined with Alprostadil.
Citrulline
Minor
The excretion of Citrulline can be decreased when combined with Alprostadil.
Cyclic adenosine monophosphate
Minor
The excretion of Cyclic adenosine monophosphate can be decreased when combined with Alprostadil.
Didanosine
Minor
The excretion of Didanosine can be decreased when combined with Alprostadil.
Caverject Toxicity & Overdose RiskThe lowest toxic dose of the drug in mice has been found to be 186mg/kg, and 228 mg/kg in rats. Signs of an overdose include difficulty breathing, a slow heartbeat, fever, low blood pressure, and flushing.

Caverject Novel Uses: Which Conditions Have a Clinical Trial Featuring Caverject?

An investigation comprising of 27 trials is currently underway to assess the potential of Caverject in treating Aquaporin 2 Deficiency, Impotence and Raynaud's Phenomenon.
Condition
Clinical Trials
Trial Phases
Aquaporin 2
3 Actively Recruiting
Phase 3, Not Applicable, Phase 2
Raynaud Disease
1 Actively Recruiting
Phase 4
Impotence
15 Actively Recruiting
Not Applicable, Phase 4, Early Phase 1, Phase 3, Phase 1, Phase 2

Caverject Reviews: What are patients saying about Caverject?

5Patient Review
9/21/2014
Caverject for Inability to have an Erection
Erection was achieved in a timely manner and lasted for 30 minutes on 20mcg. Tried it with 5mg levitra one hour before injection as these medications act at different areas of the erection pathway and had better response time and erection wise. If you are not getting the desired response from mono therapy, ask your doctor about combination protocols. Combination therapy is going to be used more commonly in the future for poor responders.
5Patient Review
7/25/2020
Caverject for Inability to have an Erection
This treatment has given me back a sex life after my radical prostatectomy.
4.7Patient Review
6/18/2022
Caverject for Inability to have an Erection
I was really nervous to give myself this injection, but it ended up being way less painful than I thought it would be. Plus, it started working within minutes and lasted for over an hour! My partner and I were thrilled. This is the only thing that has worked for my ED, and we're so grateful.
4.3Patient Review
1/13/2010
Caverject for Maintain the Patency of Ductus Arteriosus
The injection is quite painful, and it's disappointing when it doesn't lead to an erection.
4.3Patient Review
4/22/2019
Caverject for Inability to have an Erection
It's crucial to inject this medication into the right spot. You should feel some resistance and then a give; if there's resistance to the plunger, you're not in the correct area.
4Patient Review
9/7/2011
Caverject for Inability to have an Erection
The auto-injection tool makes self-injection much easier, and I'm currently at 30 units. I think this may be too high of a dose for me, as my erections tend to last for 2-3 hours now. The only downside is that it's tough for me to reach climax. Otherwise, this stuff is great!
4Patient Review
1/7/2016
Caverject for Inability to have an Erection
This treatment is effective, but unfortunately also expensive. This cost really limits how often I can use it and be active. Does anyone have suggestions for ways to get a better price?
3.7Patient Review
2/15/2010
Caverject for Inability to have an Erection
Great treatment, but sometimes it can be expensive.
3.3Patient Review
6/22/2021
Caverject for Inability to have an Erection
I've been using this medication for six months with no improvement. Recently, my GP prescribed me 10mg of Caverjet. I had some difficulty at first, but after finally being able to use it I saw a 6 out of 10 result in terms of being able to have penetrative sex again. Here's hoping that the 20mg dosage will provide even more relief.
2.7Patient Review
9/22/2017
Caverject for Inability to have an Erection
I used to be able to mix my own Caverject, which was more affordable and allowed me more control. Now, I find it difficult to use the inpulse injection both physically and because it doesn't always give me the results I need.
2Patient Review
7/26/2012
Caverject for Inability to have an Erection
I experienced pain in my penis for up to four hours after taking this treatment.
1Patient Review
9/17/2009
Caverject for Inability to have an Erection
1Patient Review
8/18/2013
Caverject for Inability to have an Erection
I have no idea how to mix the diluent and caverject powder.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about caverject

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is a Caverject injection?

"Caverject is a medicine used to treat erectile dysfunction in males. The drug is injected into the penis, which should cause an erection within 5 to 20 minutes. The erection should last no longer than an hour."

Answered by AI

How long does Caverject injection last?

"The manufacturer of this medication says it should produce an erection within 5 to 20 minutes that lasts for about 1 hour. They also recommend using it no more than 3 times a week with at least 1 day in between each dose. You should check the product for particles or discoloration before using it."

Answered by AI

How effective is Caverject?

"A study from 1996 showed that alprostadil injections were effective in 94% of cases. In 87% of cases, sexual experiences were reported to be satisfactory."

Answered by AI

Do I need a prescription for Caverject?

"Caverject is a medication used to treat the symptoms of erectile dysfunction. It may be used alone or with other medications. Caverject belongs to a class of drugs called prostaglandins, which are hormones that help regulate many body processes."

Answered by AI

Clinical Trials for Caverject

Image of McMaster Children's Hospital - Neonatal Intensive Care Unit in Hamilton, Canada.

Ibuprofen for Patent Ductus Arteriosus

< 18
All Sexes
Hamilton, Canada
Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even death if it remains open and large. When closure of PDA is needed, doctors make every attempt to do it as soon as possible. Ibuprofen is the best drug to close the PDA, but it only works for 50% of small newborns. The investigators have shown before that small newborns handle ibuprofen differently and the amount of active ibuprofen that reaches their blood can be very unpredictable. Studies have shown if enough ibuprofen reaches the body, it can close the PDA. Therefore the investigators designed this study to see whether it is possible to give each newborn the right amount of ibuprofen that their body needs to close the PDA. The investigators will compare two ways to give ibuprofen in a small number of newborns: 1 - standard amount of ibuprofen to everyone, which is the usual care or 2 - ibuprofen doses that will be changed based on how much active ibuprofen has reached the body and how well the newborn's PDA is closing. The investigators will then compare the number of PDAs closed in each group and closely monitor any possible challenges for this new practice. By doing this project, the goals can be summarized as below: A. Primary goal: To determine if it is feasible to successfully run a larger study in the future. B. Secondary goals 1. To assess how well and how safely the personalized (MIPD) method works, using a tool called WAPPS-PDA to guide dosing. 2. To compare the effectiveness and safety of the personalized method with standard ibuprofen dosing. 3. To identify drug levels in the blood (Cmin, AUC0-24, AUC0-72) that are associated with complete, partial, or no response to treatment.
Phase 2
Recruiting
McMaster Children's Hospital - Neonatal Intensive Care UnitSamira Samiee-Zafarghandy, MD, FRCPC
Image of Brigham and Women's Hospital in Boston, United States.

Oral Treprostinil for Raynaud's Disease

18+
All Sexes
Boston, MA
Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed. This makes participants fingers and toes change colors - they might turn white, then blue, and finally red as blood flow returns. It can be painful and cause numbness or tingling. When participants have Raynaud's, blood vessels react too strongly to cold or stress. Fingers and toes may turn white (blood moves away from the area), blue (lack of oxygen), or red and feel painful or tingly when warming up. These episodes usually last from a few minutes to several hours. There are two types of Raynaud's. Primary Raynaud's (also called Raynaud's disease) itself and isn't connected to other health problems. It's the most common type and affects mostly women under 30. Secondary Raynaud's (also called Raynaud's phenomenon) is caused by other diseases like lupus, scleroderma, or rheumatoid arthritis. This type tends to be more serious and may cause painful sores on fingertips called digital ulcers. For mild cases, staying warm might be enough. But if symptoms are severe, participants doctor might prescribe various medications including calcium channel blockers - blood pressure medicines that help open blood vessels, or other vasodilators - medicines that widen blood vessels. About 40% of people with scleroderma develop painful sores on their fingertips called digital ulcers. These happen when there isn't enough blood flow to heal small injuries. For severe cases with digital ulcers, doctors might use prostacyclin therapy - medicines that mimic a natural substance that opens blood vessels. Oral treprostinil is a newer pill form of prostacyclin therapy that helps improve blood flow. The investigators are conducting a research study testing whether oral treprostinil - a pill that mimics prostacyclin (a natural blood vessel opener) - can help people with severe Raynaud's that doesn't respond to usual treatments. This represents hope for better treatment options for people with the most challenging cases of this condition.
Phase 4
Waitlist Available
Brigham and Women's HospitalAaron B Waxman, MD, PhD
Have you considered Caverject clinical trials? We made a collection of clinical trials featuring Caverject, we think they might fit your search criteria.Go to Trials
Have you considered Caverject clinical trials? We made a collection of clinical trials featuring Caverject, we think they might fit your search criteria.Go to Trials
Have you considered Caverject clinical trials? We made a collection of clinical trials featuring Caverject, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security